Cholera outbreak in Nigeria's Borno state kills 74, infects over 7,000
A cholera outbreak in northeastern Nigeria's Borno state has killed 74 people and infected more than 7,000 since early May, according to Doctors Without Borders. The outbreak is occurring in a region weakened by nearly two decades of Boko Haram insurgency, where only 14% of Nigeria's population has access to safely managed drinking water. The situation highlights how conflict, poor sanitation, and limited healthcare infrastructure create conditions for rapid disease spread.
A cholera outbreak in Borno state, Nigeria has claimed 74 lives and infected over 7,000 people since beginning in early May 2026, with cases reported across 14 of the state's 27 local governments. Doctors Without Borders has treated 7,439 cholera patients at its facilities, averaging 185 admissions daily, with a single-day record of 500 patients recorded on a Friday in early June. The outbreak is unfolding in communities with fragile health systems damaged by nearly two decades of Boko Haram insurgency, compounded by widespread lack of access to safely managed drinking water—only 14% of Nigeria's 200 million population have such access according to 2020 government data. Conditions are particularly severe in Maiduguri, the densely populated state capital, and remote communities where poor sanitation, open defecation, and limited reach by health authorities accelerate transmission. Medical personnel note that by the time cases are identified in communities, local transmission has already occurred, making rapid response difficult.
What different sources said
- ABC News InternationalCenter
Nigeria’s conflict-hit Borno state battles cholera outbreak that has killed 74
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.